TNO and FAST (Financiering en Acceleratie voor Therapieontwikkeling) have launched a strategic collaboration to accelerate the development of advanced therapies, including ATMPs, radiopharmaceuticals, treatments for rare diseases, infectious diseases, and drug repurposing.
Highlights:
Shared ambition to accelerate drug discovery by leveraging TNO’s innovation capabilities and deep collaborations with industry, government, and society.
Conny Helder (former Minister of Health) appointed as FAST’s new board chair, bringing strong leadership and signalling a strengthened link with TNO in publicly funded therapy programmes.
This partnership combines TNO’s technical and operational strength with FAST’s independent expert role, aiming to scale innovations that are both effective and affordable for patients.
Read more here
Levels Dx, a diagnostics company focused on improving early detection of liver cancer, announced the successful close of its latest investment round. The new funding will support...
Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated...
Dura Vermeer Commercieel Vastgoed and Cellares has signed a long-term lease for a new IDMO Smart Factory in building Nexus (9,741 sqm LFA) at Leiden Bio Science Park. The...